Company profile RVMD

Revolution Medicines Inc
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inheren...tly rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets. Show More
Quarter analysis & expected interest

There is not enough data for Revolution Medicines near me to provide analysis

Correlation between past revenue and Revolution Medicines near me search interest

There is not enough data for Revolution Medicines near me to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Revolution Medicines near me to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Revolution Medicines login to provide analysis

Correlation between past revenue and Revolution Medicines login search interest

There is not enough data for Revolution Medicines login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Revolution Medicines login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Revolution Medicines clinical trials to provide analysis

Correlation between past revenue and Revolution Medicines clinical trials search interest

There is not enough data for Revolution Medicines clinical trials to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Revolution Medicines clinical trials to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-4630 inhibitor to provide analysis

Correlation between past revenue and RMC-4630 inhibitor search interest

There is not enough data for RMC-4630 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-4630 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-5845 inhibitor to provide analysis

Correlation between past revenue and RMC-5845 inhibitor search interest

There is not enough data for RMC-5845 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-5845 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-5552 inhibitor to provide analysis

Correlation between past revenue and RMC-5552 inhibitor search interest

There is not enough data for RMC-5552 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-5552 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-6291 inhibitor to provide analysis

Correlation between past revenue and RMC-6291 inhibitor search interest

There is not enough data for RMC-6291 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-6291 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RMC-6236 inhibitor to provide analysis

Correlation between past revenue and RMC-6236 inhibitor search interest

There is not enough data for RMC-6236 inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RMC-6236 inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Revolution Medicines stock news to provide analysis

Correlation between past revenue and Revolution Medicines stock news search interest

There is not enough data for Revolution Medicines stock news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Revolution Medicines stock news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for RVMD
Earnings date: 2024-02-26 After close
Company name: Revolution Medicines Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-07T17:51:05Z

Analyst Upgrades
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $165

2026-05-07T14:43:58Z

Analyst Upgrades
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $165

2026-05-07T13:37:14Z

Analyst Upgrades
Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $172

2026-05-07T10:50:03Z

Analyst Upgrades
Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $183

2026-05-06T22:00:00Z

GlobeNewswire
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

2026-05-06T20:02:00Z

GlobeNewswire
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

2026-04-29T20:05:00Z

GlobeNewswire
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

2026-04-22T14:29:00Z

Analyst Upgrades
Leerink Partners Maintains Outperform on Revolution Medicines, Raises Price Target to $171

2026-04-22T11:53:25Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $169 Price Target

2026-04-21T21:35:00Z

GlobeNewswire
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

2026-04-21T21:30:00Z

GlobeNewswire
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

2026-04-21T15:23:01Z

GlobeNewswire
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

2026-04-20T13:03:16Z

Analyst Upgrades
Stifel Reiterates Buy on Revolution Medicines, Raises Price Target to $215

2026-04-20T09:52:47Z

Analyst Upgrades
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $186

2026-04-19T18:00:00Z

GlobeNewswire
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting